Importantly, our data in Supplementary Figure 2, also suggest a proof-of-concept targeting of the parental or the Erlotinib-resistant NSCLC cells by CFM-4.16 in combination with Src targeting (Dasatinib) or MET targeting (Tivatinib). Here, MET is linked to non-small cell lung carcinoma.